#United States #Washington D.C. #Alzamend Neuro #Lithium Treatment #Neuroscience 2026

Alzamend Neuro's Upcoming Presentation at Neuroscience 2026

Alzamend Neuro, Inc., a company that is making strides in clinical biopharmaceutical innovation, has announced an important milestone: its Phase 1/2A clinical trial data on lithium treatment will be shared at Neuroscience 2026. This prestigious conference, organized by the Society for Neuroscience, is set to take place from November 14 to 18, 2026, in Washington, D.C.

The poster presentation, titled "Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial," encapsulates the discoveries made during extensive research on AL001, Alzamend's innovative organic lithium formulation. This study is a critical look at how lithium can reshape brain function over the course of treatment, with implications for various neuropsychiatric disorders such as Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.

Dr. Ovidiu C. Andronesi, a key figure in the research team and the principal investigator, elaborates on the significance of the findings: "Resting-state fMRI provides a non-invasive window into how our treatment modifies the brain’s functional architecture over time. The network-level changes we observe are corroborated by previous data on lithium levels in blood and tissue."

Having the opportunity to present at a renowned event like Neuroscience 2026 signifies not only recognition of Alzamend's research endeavors but also the collective effort of the neuroscience community to advance understanding of brain mechanisms related to mental health disorders. CEO Stephan Jackman expressed enthusiasm, noting, "The rigorous evidence generated by Dr. Andronesi and his team underscores how AL001 interacts with the brain. This work is crucial for millions of patients grappling with disorders where lithium plays a fundamental role."

Overview of the Study

The Phase 1/2A trial employed a randomized crossover design, allowing researchers to compare the effects of AL001 against traditional lithium carbonate in healthy participants. Each subject underwent extensive monitoring through pharmacokinetic blood sampling combined with state-of-the-art neuroimaging techniques. This included the application of a specialized, engineered head coil for high-resolution imaging of lithium concentrations in various brain regions.

This comprehensive approach assisted in assessing AL001's capability to enhance lithium delivery selectively, while potentially offering a safer profile compared to conventional lithium salts. The repeated dosing and continuous imaging helped provide insights into its behavior within the body, fulfilling FDA regulatory requirements while setting the stage for a promising future treatment option.

Notably, the researchers aimed to overcome the drawbacks associated with lithium—most notably, its narrow therapeutic window that complicates treatment for affected individuals. Traditional lithium treatments necessitate careful monitoring due to risks related to renal and thyroid function, along with gross systemic side effects. AL001's unique formulation aims to deliver effective lithium doses directly to targeted areas in the brain, thereby minimizing adverse effects.

This innovative product, combined with its potential to address substantial unmet needs across a spectrum of mental health disorders, positions AL001 as a groundbreaking option in lithium therapy.

About Alzamend Neuro

Founded to transform the landscape of mental health treatment, Alzamend Neuro focuses on creating therapeutic solutions that are both safe and effective for individuals struggling with serious conditions like Alzheimer’s and bipolar disorder. Their ongoing projects expand beyond AL001, with aspirations for new drug formulations, including a cell-based therapeutic vaccine targeting Alzheimer's pathology. These advancements reflect the company’s commitment to improving patient outcomes and enhancing quality of life across affected populations.

As the industry progresses towards better neurotherapeutics, Alzamend Neuro’s research and data presentations provide hope and validate the importance of continuous innovation in the realm of mental health. The upcoming Neuroscience 2026 meeting marks a significant opportunity for clinical findings to influence future treatments and research trajectories in neuropharmacology.